ADC Technology Market Growth Prospects, Developments Plans, Future Insights and Trends Analysis Till 2035 #9

The growth in partnership activity in recent years reflects the rising interest in this sector. During our research, we were able to identify partnership / collaboration agreements inked by around by several players engaged in this domain during the time period.

The global ADC technology market size is estimated to grow from USD 1.18 billion in 2023 to USD 4.37 billion by 2035, representing a CAGR of 11.5% during the forecast period 2023-2035.

The number of partnerships in this domain have increased significantly between 2020 and 2022, with a CAGR of ~85%. It is worth noting that majority of the deals were inked in 2022, and nearly 75% of these partnerships involved licensing of either the technology or product to be developed utilizing that technology. It is noteworthy that majority of agreements formed in 2021 were focused on the discovery of novel ADC targets for various oncological indications. Additionally, in 2023 9% of the total agreements were signed between stakeholders for variety of purposes, including product development, research and development, and technology / product integration.

The growing interest of various technology providers in enhancing their technology portfolio has led to a significant number of deals being inked in this domain. As is evident from the figure, most of the deals were inked for licensing purposes followed by research and development agreements between various stakeholders. In addition, 11% of the total deals were inked for the production of novel ADCs. Further, around 10% of the deals were inked for distribution of products.

North America based players signed the maximum number of intracontinental agreements, and also the highest number of intercontinental agreements, of which 13% were inked with the stakeholders located in Asia-Pacific and 10% with Europe based players. In Europe, the majority of the deals were inked with intracontinental players.
Stakeholders have adopted different business models to maximize the gain from ADC Linker and Conjugation Technologies.

More than half of the deals signed were for product development purposes. It is interesting to note that the majority of such deals were inked by companies which have adopted the collaborative research model. This is followed by 14% agreements formed between various stakeholders for integration of their respective technologies / products.
Catalent emerged as the most prominent player that has adopted the maximum number of business models during the time period 2014-2023. It is interesting to note that all these agreements were inked for licensing of firm’s antibody conjugation platform, a third-generation, site-specific technology intended for the treatment of mainly oncological disorders.

There are various business models that have been adopted by firms engaged in ADC linker and conjugation technologies domain. As can be inferred from the figure, technology out-licensing is the most widely adopted business model in this field. It is worth mentioning that most of such firms are small / start-ups and are focused on out licensing their technologies to test the capabilities of their platforms along with proving their credibility within this industry. The anticipated industry shift towards adopting licensing as a business model in the foreseen future is expected to provide lucrative revenue generation opportunities for the companies engaged in this domain. This is followed by 32% of the total deals inked by companies that have adopted collaborative research business model. It is interesting to note that several firms engaged in providing ADC linker and conjugation technologies believe in carrying out collaborative research efforts to expand their respective portfolios. These firms are actively integrating their capabilities for the development of novel ADC products.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.

To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/adc-technologies-market/287.html

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

The growth in partnership activity in recent years reflects the rising interest in this sector. During our research, we were able to identify partnership / collaboration agreements inked by around by several players engaged in this domain during the time period. The global ADC technology market size is estimated to grow from USD 1.18 billion in 2023 to USD 4.37 billion by 2035, representing a CAGR of 11.5% during the forecast period 2023-2035. The number of partnerships in this domain have increased significantly between 2020 and 2022, with a CAGR of ~85%. It is worth noting that majority of the deals were inked in 2022, and nearly 75% of these partnerships involved licensing of either the technology or product to be developed utilizing that technology. It is noteworthy that majority of agreements formed in 2021 were focused on the discovery of novel ADC targets for various oncological indications. Additionally, in 2023 9% of the total agreements were signed between stakeholders for variety of purposes, including product development, research and development, and technology / product integration. The growing interest of various technology providers in enhancing their technology portfolio has led to a significant number of deals being inked in this domain. As is evident from the figure, most of the deals were inked for licensing purposes followed by research and development agreements between various stakeholders. In addition, 11% of the total deals were inked for the production of novel ADCs. Further, around 10% of the deals were inked for distribution of products. North America based players signed the maximum number of intracontinental agreements, and also the highest number of intercontinental agreements, of which 13% were inked with the stakeholders located in Asia-Pacific and 10% with Europe based players. In Europe, the majority of the deals were inked with intracontinental players. Stakeholders have adopted different business models to maximize the gain from ADC Linker and Conjugation Technologies. More than half of the deals signed were for product development purposes. It is interesting to note that the majority of such deals were inked by companies which have adopted the collaborative research model. This is followed by 14% agreements formed between various stakeholders for integration of their respective technologies / products. Catalent emerged as the most prominent player that has adopted the maximum number of business models during the time period 2014-2023. It is interesting to note that all these agreements were inked for licensing of firm’s antibody conjugation platform, a third-generation, site-specific technology intended for the treatment of mainly oncological disorders. There are various business models that have been adopted by firms engaged in ADC linker and conjugation technologies domain. As can be inferred from the figure, technology out-licensing is the most widely adopted business model in this field. It is worth mentioning that most of such firms are small / start-ups and are focused on out licensing their technologies to test the capabilities of their platforms along with proving their credibility within this industry. The anticipated industry shift towards adopting licensing as a business model in the foreseen future is expected to provide lucrative revenue generation opportunities for the companies engaged in this domain. This is followed by 32% of the total deals inked by companies that have adopted collaborative research business model. It is interesting to note that several firms engaged in providing ADC linker and conjugation technologies believe in carrying out collaborative research efforts to expand their respective portfolios. These firms are actively integrating their capabilities for the development of novel ADC products. Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. To view more details on this report, click on the link https://www.rootsanalysis.com/reports/adc-technologies-market/287.html **About Roots Analysis** Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way. The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide. **Contact:** Roots Analysis Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.chaudhary@rootsanalysis.com Website: https://www.rootsanalysis.com/